Recent Updates
Recently added Catalysts
BEAM Positive Sentiment

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Beam Therapeutics Inc. has announced its participation in several investor conferences, including fireside chats. This engagement reflects the company's commitment to connecting with the investment community and discussing its innovations in precision genetic medicines through base editing. The events are set to take place in September 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Beam Therapeutics is actively engaging with investors.
  • Participation in multiple conferences indicates strong investor interest.
  • The company is showcasing its advancements in precision genetic medicines.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
8.7%
average across 2 past catalysts
Cash runway
~51 mo
Minimal dilution risk
Lead asset
BEAM-302
Phase 1 · Alpha 1-Antitrypsin Deficiency

Full Press Release Details

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Wells

Frequently Asked Questions

What conferences will Beam Therapeutics attend?

Beam Therapeutics will participate in several investor conferences in September 2026.

What is the focus of Beam Therapeutics?

Beam Therapeutics focuses on developing precision genetic medicines through base editing.

What type of events will Beam participate in?

Beam will engage in fireside chats at the upcoming investor conferences.

When are the investor conferences scheduled?

The investor conferences featuring Beam Therapeutics are scheduled for September 2026.

ShareAdd on Google
Tags: BEAM Viatris Investor Conferences Healthcare Beam Therapeutics investor conferences genetic medicines base editing biotechnology
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$1153M liquidity · $22M/mo burn
~51 mo
Minimal dilution risk
Lead asset
BEAM-302Phase 1
Alpha 1-Antitrypsin Deficiency →

Catalyst track record

+52%
best trade around BEAM's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for BEAM.

See every catalyst's timing & PoA →